ABSTRACT
OBJETIVO: Describir el uso de carbapenémicos en pacientes pediátricos hospitalizados fuera de las unidades de cuidados intensivos y oncohematología, y evaluar la adecuación de su prescripción a un protocolo terapéutico. PACIENTES Y MÉTODOS: Estudio retrospectivo observacional, entre enero de 2009 y diciembre de 2010, sobre la utilización de carbapenémicos en niños hospitalizados, por patología infecciosa comunitaria y relacionada con asistencia sanitaria, en el área infantil del Hospital Universitari Vall d'Hebrón, en Barcelona, excluyendo las unidades de cuidados intensivos, neonatología y oncohematología. Se recogieron datos clínicos y de consumo de antibióticos, facilitados por el Servicio de Farmacia. RESULTADOS: Cumplían los criterios de inclusión 51 episodios. En el 31,4% se indicó un carbapenémico como tratamiento empírico inicial; en el resto fue como tratamiento de rescate. Se adecúan a las indicaciones del protocolo el 70,6% de las prescripciones empíricas y el 87,5% de las dirigidas. Globalmente, el 77,6% de las prescripciones de un carbapenémico se ajustaron a las indicaciones del protocolo. En los pacientes con un ingreso previo o una enfermedad de base la prescripción empírica tiene una mejor adecuación. Factores como el diagnóstico al ingreso, la edad o la antibioterapia previa al ingreso no mostraron ninguna tendencia respecto a la indicación empírica de un carbapenémico. CONCLUSIONES: La existencia de un protocolo de indicaciones de tratamiento con carbapenémicos establecido desde 2007 en el hospital ha permitido unos resultados de adecuación de la prescripción significativamente superiores a los obtenidos en otros estudios
OBJECTIVE: To describe the use of carbapenems in children hospitalised outside intensive care and onco-haematology units, and assess adherence to a therapeutic protocol. PATIENTS AND METHODS: A retrospective observational study was conducted on the use of carbapenems between January 2009 and December 2010. The study included children with a community-acquired infectious disease or a health care-associated infectious disease, and who were admitted to paediatric areas of the Vall d'Hebron University Hospital (Barcelona, Spain), other than intensive care, neonatology and onco-haematology units. Clinical data were collected and antibiotic consumption data were provided by the Pharmacy Department. RESULTS: A total of 51 episodes fulfilled the inclusion criteria. Carbapenem as initial empirical treatment was indicated in 31.4%, and applied as rescue therapy in the remainder. The instructions of the protocol were adhered to in 70.6% of the empirical and 87.5% of the targeted prescriptions (77.6% overall). A better match was found for empirical carbapenem in patients with a previous admission or underlying condition. Factors such as diagnosis, age or antibiotic use prior to admission did not affect the empirical indication of carbapenem. CONCLUSIONS: The establishment of a treatment protocol with carbapenem indications in our centre since 2007 has yielded significantly better results on the appropriateness of the prescription than those obtained in other studies
Subject(s)
Humans , Male , Female , Child , Carbapenems/metabolism , Carbapenems/therapeutic use , Anti-Infective Agents/therapeutic use , Community-Acquired Infections/complications , Community-Acquired Infections/immunology , Community-Acquired Infections/microbiology , Clinical Protocols , Community Medicine/methods , Retrospective StudiesABSTRACT
OBJECTIVE: To describe the use of carbapenems in children hospitalised outside intensive care and onco-haematology units, and assess adherence to a therapeutic protocol. PATIENTS AND METHODS: A retrospective observational study was conducted on the use of carbapenems between January 2009 and December 2010. The study included children with a community-acquired infectious disease or a health care-associated infectious disease, and who were admitted to paediatric areas of the Vall d'Hebron University Hospital (Barcelona, Spain), other than intensive care, neonatology and onco-haematology units. Clinical data were collected and antibiotic consumption data were provided by the Pharmacy Department. RESULTS: A total of 51 episodes fulfilled the inclusion criteria. Carbapenem as initial empirical treatment was indicated in 31.4%, and applied as rescue therapy in the remainder. The instructions of the protocol were adhered to in 70.6% of the empirical and 87.5% of the targeted prescriptions (77.6% overall). A better match was found for empirical carbapenem in patients with a previous admission or underlying condition. Factors such as diagnosis, age or antibiotic use prior to admission did not affect the empirical indication of carbapenem. CONCLUSIONS: The establishment of a treatment protocol with carbapenem indications in our centre since 2007 has yielded significantly better results on the appropriateness of the prescription than those obtained in other studies.